Phase II study of recombinant human granulocyte colony-stimulating factor in children undergoing bone marrow transplantation.


Twenty-three children with congenital or acquired hematological disorders and 8 children with solid tumors received filgrastim at a dose of 5 micrograms/Kg by a daily 2-hour infusion following allogeneic (18 cases) or autologous (13 cases) bone marrow transplantation (group I). The results were compared with those of a disease, age and type of transplant… (More)


  • Presentations referencing similar topics